LOUISVILLE, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2024. “The second quarter marks sustained excellence in our execution, resulting in outstanding revenue growth coupled with consistently strong gross margins, and continued improvement on our path to profitability,” said Scott Hutton, CEO of Biodesix. “The team’s performance led to 51% growth in reven
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
